Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward Keystone

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|January 23, 2019
Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III StudyDésirée van der Heijde, Vibeke Strand, Yoshiya Tanaka, et al.
Expert Opinion on Biological Therapy|June 21, 2024
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I studyKyung-Sang Yu, Hyunwook Ryu, Dongseong Shin, et al.
Arthritis and Rheumatism|April 9, 2005
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)Christian E Antoni, Arthur Kavanaugh, Bruce Kirkham, et al.
Arthritis Care & Research|February 17, 2018
High Adherence to System-Level Performance Measures for Rheumatoid Arthritis in a National Early Arthritis Cohort Over Eight YearsClaire E H Barber, Orit Schieir, Diane Lacaille, et al.
Expert Opinion on Investigational Drugs|May 26, 2023
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I studyKyung-Sang Yu, Byungwook Kim, Dongseong Shin, et al.
Arthritis Research & Therapy|February 6, 2021
Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized studyJonathan Kay, Janusz Jaworski, Rafal Wojciechowski, et al.
Arthritis Care & Research|June 28, 2012
Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activityJeffrey R Curtis, Annette H van der Helm-van Mil, Rachel Knevel, et al.
RMD Open|October 18, 2024
Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47Josef S Smolen, Jakub Trefler, Artur Racewicz, et al.
Arthritis and Rheumatism|January 26, 2013
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic studyDésirée van der Heijde, Yoshiya Tanaka, Roy Fleischmann, et al.
Rheumatology (Oxford, England)|June 18, 2021
Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritisDaniel E Furst, Janusz Jaworski, Rafal Wojciechowski, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
Arthritis & Rheumatology (Hoboken, N.J.)|January 23, 2019
Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III StudyDésirée van der Heijde, Vibeke Strand, Yoshiya Tanaka, et al.
Expert Opinion on Biological Therapy|June 21, 2024
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I studyKyung-Sang Yu, Hyunwook Ryu, Dongseong Shin, et al.
Arthritis and Rheumatism|April 9, 2005
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)Christian E Antoni, Arthur Kavanaugh, Bruce Kirkham, et al.
Arthritis Care & Research|February 17, 2018
High Adherence to System-Level Performance Measures for Rheumatoid Arthritis in a National Early Arthritis Cohort Over Eight YearsClaire E H Barber, Orit Schieir, Diane Lacaille, et al.
Expert Opinion on Investigational Drugs|May 26, 2023
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I studyKyung-Sang Yu, Byungwook Kim, Dongseong Shin, et al.
Arthritis Research & Therapy|February 6, 2021
Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized studyJonathan Kay, Janusz Jaworski, Rafal Wojciechowski, et al.
Arthritis Care & Research|June 28, 2012
Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activityJeffrey R Curtis, Annette H van der Helm-van Mil, Rachel Knevel, et al.
RMD Open|October 18, 2024
Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47Josef S Smolen, Jakub Trefler, Artur Racewicz, et al.
Arthritis and Rheumatism|January 26, 2013
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic studyDésirée van der Heijde, Yoshiya Tanaka, Roy Fleischmann, et al.
Rheumatology (Oxford, England)|June 18, 2021
Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritisDaniel E Furst, Janusz Jaworski, Rafal Wojciechowski, et al.
Pageof 9